Better Days Are Coming! With your help, we CAN cure Angelman syndrome. Please join the FAST community in our 2022 Cure Angelman Now (CAN) campaign by sharing our message, making a donation, or both.

Research funded by FAST identified a way to turn on a gene that is normally turned off in the brain. FAST took this discovery and started its own biotechnology company to move this technology from the laboratory into human clinical trials. Trials were initiated in 2020 and early preliminary results suggest this therapeutic may effectively treat the symptoms of Angelman syndrome.

We have more exciting news - this approach is just one of the ways FAST is leading the efforts to develop effective treatments for Angelman syndrome. FAST funds multiple programs aimed at developing therapeutics to treat the root cause of Angelman syndrome as well as therapeutics that may treat certain symptoms. In fact, FAST is the largest non-governmental funder of Angelman specific research and relies on grassroots donors like you to support these groundbreaking programs. To date, FAST has funded $25.6M in research which advances the therapeutics in the pipeline to achieve our mission to cure Angelman syndrome. We won't stop until meaningful therapeutics are available for all individuals living with Angelman syndrome, regardless of age or genotype.

We look forward to sharing amazing updates and progress with you throughout the year on our website (cureangelman.org), social media (Instagram & Twitter: @cureangleman) and in our newsletters (sign up through our website).

Please help our FAST community reach our goal. Please be aware, at the request of our community, we will be leaving CAN campaign pages open through until December 31, 2022. However, fundraising totals qualifying for the CAN contest end on October 15, 2022 given prize packages include 2022 Global Science Summit and Gala airfare and accommodations. We thank you for being part of FAST's mission to Cure Angelman Now and we thank you in advance for your generosity!